Chief Executive Officer
Piers Whitehead has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health. Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies. As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company's second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr Whitehead holds a BA with honours from Oxford University.
Todd Suscovich, PhD.
Chief Technical Officer
Dr. Todd Suscovich, Chief Technical Officer, leads the implementation and further development of the Systems Serology platform at SeromYx, with a focus on expanding the use of this technology beyond the Infectious Disease space. Prior to joining SeromYx, his research broadly focused on how molecular events affect both the induction and regulation of the immune response during autoimmunity and infection and how these various pathways and underlying mechanisms can be manipulated to prevent/treat infection and disease. Since 2012, he has worked closely with Dr. Alter, leading the development and optimization of the Systems Serology platform, using this technology to identify antibody features and functions that are associated with protection from HIV infection. Recognizing the broad applicability of this platform in identifying correlates of protection in infection and vaccination beyond HIV, he spearheaded the adaptation and utilization of the Systems Serology technology across a broad range of globally relevant pathogens and diseases including tuberculosis, malaria, RSV, Ebola virus, Zika virus, and pertussis. Todd holds a Bachelor of Science in Molecular Biology from the University of Pittsburgh and a doctorate in Virology from Harvard Medical School.
Galit Alter, PhD.
Chief Scientific Officer (Consulting)
Galit Alter received her PhD in experimental medicine from McGill University, and is currently a Professor in Medicine at Harvard Medical School and a faculty member at the Ragon Institute of MGH, MIT, and Harvard. Her research interests lie at the intersection of the innate immune response and the adaptive humoral immune response, with a focus on defining the role of innate immune recruiting antibodies in providing specificity to the innate immune system to kill virally infected cells. In this capacity, Dr. Alter has developed a suite of antibody profiling assays, collectively Systems Serology, that aim at gaining a deeper appreciation of the correlates of humoral immune activity against HIV and beyond. Galit serves as SeromYx CSO on a part-time consulting basis.